CureVac NV (WBO:CVAC) Receivables Turnover : 0.85 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CureVac NV's Revenue for the three months ended in Mar. 2024 was €12.37 Mil. CureVac NV's average Accounts Receivable for the three months ended in Mar. 2024 was €14.49 Mil. Hence, CureVac NV's Receivables Turnover for the three months ended in Mar. 2024 was 0.85.

CureVac NV Receivables Turnover Historical Data

The historical data trend for CureVac NV's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Receivables Turnover Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

1.65

5.85

10.55

5.44

5.21

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															1.47	1.54	1.95	1.82	0.85

Competitive Comparison of CureVac NV's Receivables Turnover

For the Biotechnology subindustry, CureVac NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where CureVac NV's Receivables Turnover falls into.

CureVac NV Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

CureVac NV's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	53.758	/ (	(6.295	+	14.326)	/	2 )
=	53.758	/	10.3105
=	5.21

CureVac NV's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	12.373	/ (	(14.326	+	14.644)	/	2 )
=	12.373	/	14.485
=	0.85

CureVac NV (WBO:CVAC) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

CureVac NV Receivables Turnover Related Terms

Thank you for viewing the detailed overview of CureVac NV's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.